HomeAI · summaries
Storia in 4 fonti
Another heart drug fails, shocking cardiologists
Medical specialists are reeling after experimental medication did not pass a massive clinical trial, upending hopes for a new era of disease care.
Confronto fonti
4 prospettive sulla stessa storiaTimeline cronologica
- ·
endpoints.news
Novartis' Phase 3 cardiovascular study miss raises the stakes for Amgen, Lilly
Novartis' pelacarsen fails Lp(a)HORIZON, the third major CV outcomes trial miss in two months, as Amgen, Lilly and others push ahead.
- ·
Updated: Novartis sinks after second disastrous trial failure, this time of Avidity-acquired drug
Novartis' del-desiran misses HARBOR trial's primary endpoint, adding to pelacarsen miss and CAR-T deaths; shares sink 10%.
